Eli Lilly unveils oncology data: Eli Lilly stock sits 1.64 percent below its 52-week high
Published on 10/19/2026 at 09:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOncology pipeline and earnings dates
- On October 18, 2026, Lilly announced four oncology data presentations for ESMO.
- In second-quarter 2026, revenue was USD 22.97 billion, up 47.7 percent year over year.
- Eli Lilly stock trades at EUR 1,119.10 at 9:50 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.38 percent below the Xetra close of October 16, 2026.
Eli Lilly and Co. (ISIN US5324571083) was trading at EUR 1,119.10 at Lang & Schwarz on October 19, 2026, at 9:50 a.m. CEST, 0.38 percent below the Xetra close of October 16, 2026 at EUR 1,123.40. The company had announced four oncology data presentations for the European Society for Medical Oncology Congress, while the stock sat 1.64 percent below its 52-week high of EUR 1,137.80. PR Newswire reported the announcement on October 18, 2026.
What is driving the pipeline?
The oncology program covers first Phase 1 data for sofetabart mipitecan in ovarian cancer, updated olomorasib data in lung cancer, and Phase 3 presentations for selpercatinib and abemaciclib. The event gives investors a dated view of pipeline breadth beyond Lilly's diabetes and obesity franchises.
The presentations are scheduled for the ESMO Congress in Madrid from October 23 to October 27, 2026. Sofetabart mipitecan and olomorasib remain investigational, so the clinical data are development milestones rather than commercial revenue.
Three events changed the picture
On October 9, 2026, Lilly reported 482 differentially expressed proteins versus 140 for Taltz alone in a Phase 3b analysis involving 274 participants, according to Eli Lilly and Company. On October 15, 2026, Omvoh data showed comprehensive disease control in 27.7 percent of treated ulcerative-colitis patients versus 14.0 percent receiving placebo, according to Eli Lilly and Company. On October 18, 2026, Lilly announced the four oncology presentations for ESMO through PR Newswire.
What does the earnings setup mean?
Second-quarter 2026 revenue reached USD 22.97 billion, up 47.7 percent from the same quarter a year earlier, while diluted earnings per share were USD 7.94. Operating cash flow was USD 10.69 billion in the quarter. The revenue comparison shows why upcoming oncology data matter strategically: they add clinical breadth to a business whose recent scale is already substantial.
When are the next checkpoints?
The ESMO Congress runs from October 23 to October 27, 2026, and Lilly's next quarterly results and conference call are scheduled for October 29, 2026, according to Eli Lilly and Company.
Stock stays below the yearly high
The EUR 1,119.10 quote is EUR 18.70 below the 52-week high and remains within the EUR 685.50 to EUR 1,137.80 range. The primary NYSE listing was last quoted at USD 1,257.03 on October 16, 2026 at 4:00 p.m. ET, with a market capitalization of USD 1.2 trillion.
The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.
Eli Lilly stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 19, 2026, 9:50 a.m. CEST): EUR 1,119.10
- Change versus Xetra close: minus 0.38 percent
- Xetra close (October 16, 2026): EUR 1,123.40
- Market capitalization: USD 1.2 trillion (as of October 16, 2026)
- 52-week range: EUR 685.50-EUR 1,137.80 (as of October 19, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
Market context: Market report S&P 500.
